1-[1-(4-甲基-1-哌嗪基)环戊基]甲胺 | 959240-31-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-[1-(4-甲基-1-哌嗪基)环戊基]甲胺
• 英文名称: 1-[1-(4-Methyl-1-piperazinyl)cyclopentyl]methanamine
• 英文别名: [1-(4-methylpiperazin-1-yl)cyclopentyl]methanamine
• CAS: 959240-31-4
• 化学式: C₁₁H₂₃N₃
• 分子量: 197.324
• InChiKey: KUTJXIZFVLYHEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  邻乙氧基苯甲酰氯 、 1-[1-(4-甲基-1-哌嗪基)环戊基]甲胺 在 吡啶 作用下， 反应 24.0h， 生成 2-ethoxy-N-[[1-(4-methylpiperazin-1-yl)cyclopentyl]methyl]benzamide
  参考文献：
  名称：

  Discovery of a novel series of selective HCN1 blockers

  摘要：

  The discovery of a series of novel, potent, and selective blockers of the cyclic nucleotide-modulated channel HCN1 is disclosed. Here we report an SAR study around a series of selective blockers of the HCN1 channel. Utilization of a high-throughput VIPR assay led to the identification of a novel series of 2,2-disubstituted indane derivatives, which had moderate selectivity and potency at HCN1. Optimization of this hit led to the identification of the potent, 1,1-disubstituted cyclohexane HCN1 blocker, 2-ethoxy- N-(( 1-(4-isopropylpiperazin-1-yl) cyclohexyl) methyl) benzamide. The work leading to the discovery of this compound is described herein. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.051
• 作为产物：
  描述：

  环戊酮 在 lithium aluminium tetrahydride 、 zinc(II) iodide 作用下， 以 甲醇 、 乙醚 为溶剂， 反应 8.0h， 生成 1-[1-(4-甲基-1-哌嗪基)环戊基]甲胺
  参考文献：
  名称：

  Discovery of a novel series of selective HCN1 blockers

  摘要：

  The discovery of a series of novel, potent, and selective blockers of the cyclic nucleotide-modulated channel HCN1 is disclosed. Here we report an SAR study around a series of selective blockers of the HCN1 channel. Utilization of a high-throughput VIPR assay led to the identification of a novel series of 2,2-disubstituted indane derivatives, which had moderate selectivity and potency at HCN1. Optimization of this hit led to the identification of the potent, 1,1-disubstituted cyclohexane HCN1 blocker, 2-ethoxy- N-(( 1-(4-isopropylpiperazin-1-yl) cyclohexyl) methyl) benzamide. The work leading to the discovery of this compound is described herein. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.051

文献信息

• INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME
  申请人：University Health Network

  公开号：US20140371202A1

  公开（公告）日：2014-12-18

  The present teaching provide indazole compounds represented by Structural Formulae (I) or (I′) or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast cancer cells, colon cancer cells, and ovarian cancer cells.

  本教学提供由结构式（I）或（I'）所代表的吲唑化合物或其药学上可接受的盐。还描述了制备药物组合物和使用方法，作为蛋白激酶抑制剂，例如TTK蛋白激酶，极化样激酶4（PLK4）和极化激酶，对乳腺癌细胞，结肠癌细胞和卵巢癌细胞具有抗癌活性。
• US9580390B2
  申请人：——

  公开号：US9580390B2

  公开（公告）日：2017-02-28
• Discovery of a novel series of selective HCN1 blockers
  作者：Kelly J. McClure、Michael Maher、Nancy Wu、Sandra R. Chaplan、William A. Eckert、Dong H. Lee、Alan D. Wickenden、Michelle Hermann、Brett Allison、Natalie Hawryluk、J. Guy Breitenbucher、Cheryl A. Grice

  DOI：10.1016/j.bmcl.2011.07.051

  日期：2011.9

  The discovery of a series of novel, potent, and selective blockers of the cyclic nucleotide-modulated channel HCN1 is disclosed. Here we report an SAR study around a series of selective blockers of the HCN1 channel. Utilization of a high-throughput VIPR assay led to the identification of a novel series of 2,2-disubstituted indane derivatives, which had moderate selectivity and potency at HCN1. Optimization of this hit led to the identification of the potent, 1,1-disubstituted cyclohexane HCN1 blocker, 2-ethoxy- N-(( 1-(4-isopropylpiperazin-1-yl) cyclohexyl) methyl) benzamide. The work leading to the discovery of this compound is described herein. (C) 2011 Elsevier Ltd. All rights reserved.